Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review

American Journal of Orthopsychiatry

Volumn 86, Issue 5, 2016, Pages 477-485

  Sohler, Nancy ^a   Adams, Ben G ^b   Barnes, David M ^b   Cohen, Gregory H ^b   Prins, Seth J ^b   Schwartz, Sharon ^b  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b Howard Hughes Medical Institute   (United States)

Author keywords

Antipsychotic medications; Mental health services; Psychosis

Indexed keywords

CONSENSUS; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; LONG TERM CARE; PSYCINFO; SYSTEMATIC REVIEW; DISEASE MANAGEMENT; EVIDENCE BASED MEDICINE; SCHIZOPHRENIA;

NEUROLEPTIC AGENT;

ANTIPSYCHOTIC AGENTS; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS; SCHIZOPHRENIA;

EID: 84949921502     PISSN: 00029432     EISSN: 19390025     Source Type: Journal    
DOI: 10.1037/ort0000106     Document Type: Article

References (46)

1. American Psychiatric Association. (2006). American Psychiatric Association practice guidelines for the treatment of psychiatric disorders: Compendium. Arlington, VA: Author.
2. Appelbaum, P. S. (1996). Drug-free research in schizophrenia: An overview of the controversy. IRB: Ethics and Human Research, 18, 1-5. http://dx.doi.org/10.2307/3563910
3. Bockoven, J. S., Solomon, H. C. (1975). Comparison of two five-year follow-up studies: 1948 to 1952 and 1967 to 1972. The American Journal of Psychiatry, 132, 796-801. http://dx.doi.org/10.1176/ajp.132 .8.796
4. Boonstra, G., Burger, H., Grobbee, D. E., Kahn, R. S. (2011). Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: Results from an aborted randomised trial. International Journal of Psychiatry in Clinical Practice, 15, 128- 134. http://dx.doi.org/10.3109/13651501.2010.534801
5. Caroff, S. N., Hurford, I., Lybrand, J., Campbell, E. C. (2011). Movement disorders induced by antipsychotic drugs: Implications of the CATIE schizophrenia trial. Neurologic Clinics, 29, 127-148, viii. http:// dx.doi.org/10.1016/j.ncl.2010.10.002
6. Carpenter, W. T., Jr. (1997). The risk of medication-free research. Schizophrenia Bulletin, 23, 11-18. http://dx.doi.org/10.1093/schbul/23.1.11
7. Carpenter, W. T., Jr., Heinrichs, D. W., Hanlon, T. E. (1987). A comparative trial of pharmacologic strategies in schizophrenia. The American Journal of Psychiatry, 144, 1466-1470. http://dx.doi.org/10 .1176/ajp.144.11.1466
8. Carpenter, W. T., Jr., Schooler, N. R., Kane, J. M. (1997). The rationale and ethics of medication-free research in schizophrenia. Archives of General Psychiatry, 54, 401-407. http://dx.doi.org/10.1001/archpsyc .1997.01830170015002
9. Crow, T. J., MacMillan, J. F., Johnson, A. L., Johnstone, E. C. (1986). A randomised controlled trial of prophylactic neuroleptic treatment. The British Journal of Psychiatry, 148, 120-127. http://dx.doi.org/10.1192/ bjp.148.2.120
10. Engelhardt, D. M., Rosen, B., Freedman, N., Margolis, R. (1967). Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization-A reevaluation. Archives of General Psychiatry, 16, 98 -101. http://dx.doi.org/10.1001/archpsyc.1967 .01730190100013
11. Frese, F. J., III, Stanley, J., Kress, K., Vogel-Scibilia, S. (2001). Integrating evidence-based practices and the recovery model. Psychiatric Services, 52, 1462-1468. http://dx.doi.org/10.1176/appi.ps.52.11.1462
12. Gilbert, P. L., Harris, M. J., McAdams, L. A., Jeste, D. V. (1995). Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry, 52, 173-188. http://dx.doi.org/ 10.1001/archpsyc.1995.03950150005001
13. Harrow, M., Jobe, T. H. (2013). Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophrenia Bulletin, 39, 962-965. http://dx.doi.org/10.1093/schbul/sbt034
14. Harrow, M., Jobe, T. H., Faull, R. N. (2012). Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychological Medicine, 42, 2145- 2155. http://dx.doi.org/10.1017/S0033291712000220
15. Healy, D. (1997). The antidepressant era. Cambridge, MA: Harvard University Press.
16. Hogarty, G. E., Goldberg, S. C., Schooler, N. R., Ulrich, R. F. (1974). Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Archives of General Psychiatry, 31, 603-608. http://dx.doi.org/10.1001/archpsyc.1974.01760170005001
17. Insel, T. Director's blog: Antipsychotics: Taking the long view. Retrieved from http://www.nimh.nih.gov/about/director/index.shtml
18. Jacobson, N., Greenley, D. (2001). What is recovery? A conceptual model and explication. Psychiatric Services, 52, 482-485. http://dx.doi .org/10.1176/appi.ps.52.4.482
19. Kirkby, K. C. (2005). Social context and health consequences of the antipsychotics introduction. Annals of Clinical Psychiatry, 17, 141-146. http://dx.doi.org/10.1080/10401230591002066
20. Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., the Schizophrenia Patient Outcomes Research Team (PORT). (2010). The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2009. Schizophrenia Bulletin, 36, 94-103. http://dx.doi.org/10.1093/schbul/sbp130
21. Krieg, R. G. (2001). An interdisciplinary look at the deinstitutionalizaton of the mentally ill. The Social Science Journal, 38, 367-380. http://dx .doi.org/10.1016/S0362-3319(01)00136-7
22. Lehmann, H. E. (1966). Psychopharmacotherapy. In D. Healy (Ed.), The psychopharmacologists (Vol. 1, pp. 159-186). London, England: Arnold. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., örey, D., Richter, F., . . .
23. London, England: Arnold. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., örey, D., Richter, F., Davis, J. M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. The Lancet, 382, 951-962. http://dx.doi.org/10.1016/S0140-6736(13) 60733-3
24. Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., Davis, J. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet, 379, 2063-2071. http://dx.doi.org/10.1016/S0140- 6736(12)60239-6
25. Lieberman, J. A., III. (2004). Metabolic changes associated with antipsychotic use. Primary Care Companion to the Journal of Clinical Psychiatry, 6, 8-13.
26. Lieberman, J. A., Stroup, T. S. (2011). The NIMH-CATIE Schizophrenia Study: What did we learn? The American Journal of Psychiatry, 168, 770-775. http://dx.doi.org/10.1176/appi.ajp.2011.11010039
27. López-Muñoz, F., Alamo, C., Cuenca, E., Shen, W. W., Clervoy, P., Rubio, G. (2005). History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry, 17, 113-135. http://dx .doi.org/10.1080/10401230591002002
28. May, P. R., Tuma, A. H., Dixon, W. J., Yale, C., Thiele, D. A., Kraude, W. H. (1981). Schizophrenia. A follow-up study of the results of five forms of treatment. Archives of General Psychiatry, 38, 776-784. http:// dx.doi.org/10.1001/archpsyc.1981.01780320056006
29. McGlashan, T. H. (2006). Rationale and parameters for medication-free research in psychosis. Schizophrenia Bulletin, 32, 300-302. http://dx .doi.org/10.1093/schbul/sbj045
30. McGorry, P., Alvarez-Jimenez, M., Killackey, E. (2013). Antipsychotic medication during the critical period following remission from firstepisode psychosis: Less is more. Journal of the American Medical Association Psychiatry, 70, 898 -900. http://dx.doi.org/10.1001/ jamapsychiatry.2013.264
31. McGorry, P. D., Yung, A., Phillips, L. (2001). Ethics and early intervention in psychosis: Keeping up the pace and staying in step. Schizophrenia Research, 51, 17-29. http://dx.doi.org/10.1016/S0920- 9964(01)00235-3
32. McWalter, H. S., Mercer, R., Sutherland, M., Watt, A. (1961). Outcomes of treatment of schizophrenia in a north-east Scottish mental hospital. The American Journal of Psychiatry, 118, 529-533. http://dx.doi.org/ 10.1176/ajp.118.6.529
33. Moilanen, J., Haapea, M., Miettunen, J., Jääskeläinen, E., Veijola, J., Isohanni, M., Koponen, H. (2013). Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication - A 10- year follow-up of the Northern Finland 1966 Birth Cohort study. European Psychiatry, 28, 53-58. http://dx.doi.org/10.1016/j.eurpsy.2011.06 .009
34. Moncrieff, J., Leo, J. (2010). A systematic review of the effects of antipsychotic drugs on brain volume. Psychological Medicine, 40, 1409-1422. http://dx.doi.org/10.1017/S0033291709992297
35. Mosher, L. R., Menn, A. Z. (1978). Community residential treatment for schizophrenia: Two-year follow-up. Hospital & Community Psychiatry, 29, 715-723.
36. Nishikawa, T., Tsuda, A., Tanaka, M., Koga, I., Uchida, Y. (1982). Prophylactic effect of neuroleptics in symptom-free schizophrenics. Psychopharmacology, 77, 301-304. http://dx.doi.org/10.1007/BF00432759
37. Odegard. (1964). Pattern of discharge from Norwegian psychiatric hospitals before and after the introduction of psychotropic drugs. American Journal of Psychiatry, 120, 772-778.
38. Pietzcker, A., Gaebel, W., Kopcke, W., Linden, M., Muller, P., Muller- Spahn, F., Tegeler, J. (1993). Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia-2-year results of a German multicenter study. Journal of Psychiatric Research, 27, 321-339. http://dx.doi.org/10.1016/0022-3956(93)90059-B
39. Pritchard, M. (1967). Prognosis of schizophrenia before and after pharmacotherapy: I. Short term outcome. The British Journal of Psychiatry, 113, 1345-1352. http://dx.doi.org/10.1192/bjp.113.505.1345
40. Rappaport, M., Hopkins, H. K., Hall, K., Belleza, T., Silverman, J. (1978). Are there schizophrenics for whom drugs may be unnecessary or contraindicated? International Pharmacopsychiatry, 13, 100-111.
41. Tiihonen, J., Wahlbeck, K., Lönnqvist, J., Klaukka, T., Ioannidis, J. P., Volavka, J., Haukka, J. (2006). Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study. BMJ: British Medical Journal, 333, 224-220. http://dx.doi.org/10.1136/bmj.38881.382755.2F
42. Torgalsbøen, A.-K. (2012). Sustaining full recovery in schizophrenia after 15 years: Does resilience matter? Clinical Schizophrenia & Related Psychoses, 5, 193-200. http://dx.doi.org/10.3371/CSRP.5.4.3
43. Whitaker, R. (2004). The case against antipsychotic drugs: A 50-year record of doing more harm than good. Medical Hypotheses, 62, 5-13. http://dx.doi.org/10.1016/S0306-9877(03)00293-7
44. Whitaker, R. (2010). Anatomy of an epidemic. New York, NY: Broadway Paperbacks.
45. Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., Nienhuis, F. J. (2013). Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trial. Journal of the American Medical Association Psychiatry, 70, 913-920. http://dx.doi.org/10.1001/jamapsychiatry.2013.19
46. Zubin, J. (1956). Role of prognostic indicators in the evaluation of therapy. In Psychopharmacology: Problems in evaluation. Proceedings of a conference on the evaluation of pharmacotherapy in mental illness (p. 347). Washington, DC: National Academy of Sciences.